Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing – Initial Report of the SABR-Dual Trial-Reference-Cited by-同舟云学术

Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing – Initial Report of the SABR-Dual Trial

Published:2024-07 Issue: Volume: Page:
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Fredman Elisha,Moore Assaf,Icht Oded,Tschernichovsky Roi,Shemesh Danielle,Bragilovski Dimitri,Kindler Jonathan,Golan Shay,Shochet Tzippora,Limon Dror

Funder

Israel Institute

Boston Scientific Corporation

Publisher

Elsevier BV

Reference20 articles.

1. Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies;Jackson;Int J Radiat Oncol Biol Phys,2019

2. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial;Tree;Lancet Oncol,2022

3. National Comprehensive Cancer Network. Prostate Cancer (Version 3.2024). Accessed March 13, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial;Michalski;JAMA Oncol,2018

5. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial;Greco;JAMA Oncol,2021